|Videos|March 23, 2023

Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

Author(s)Kathryn E. Beckermann, MD, PhD, Moshe Ornstein, MD, MA, Mehmet Asim Bilen, MD

Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.

Episodes in this series

EP. 1 Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

EP. 1 Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

EP. 2 Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

EP. 3 Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

EP. 3 Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

EP. 4 Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

EP. 4 Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

EP. 5 Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

EP. 5 Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

EP. 6 Treatment Approaches for Patients with RCC and Bone Metastases

EP. 6 Treatment Approaches for Patients with RCC and Bone Metastases

EP. 7 Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

EP. 7 Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

EP. 8 Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

EP. 8 Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

EP. 9 Updates in the Adjuvant Treatment of Metastatic RCC

EP. 9 Updates in the Adjuvant Treatment of Metastatic RCC

$EP. 10 Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC$

EP. 10 Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC

$EP. 11 Preferred Treatment Regimens for Refractory RCC$

EP. 11 Preferred Treatment Regimens for Refractory RCC

EP. 12 Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

EP. 12 Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

EP. 13 Genetic Counseling for Patients with Non-Clear Cell RCC

EP. 13 Genetic Counseling for Patients with Non-Clear Cell RCC

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Adanma Ayanambakkam, MD, MS

August 23rd, 2026

Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC

Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.

FDA

August 20th, 2026

FDA Grants Breakthrough Therapy and Fast Track Status to 68Ga-NYM096 in ccRCC

The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.

Clear cell RCC: ©Image by Ashling Wahner & MJH Life Sciences Using AI

August 14th, 2026

Pembrolizumab Plus Denosumab Yields Responses in Pretreated Advanced Clear Cell RCC

Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR TKI–pretreated advanced clear cell renal cell carcinoma.

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC

The OncFive: Top Oncology Articles for the Week of 8/16

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer